| Original language | English (US) |
|---|---|
| Pages (from-to) | S342-S343 |
| Journal | Pediatrics |
| Volume | 146 |
| DOIs |
|
| State | Published - Dec 2020 |
Funding
REVIEWER COMMENTS: This study reported high adherence and follow-up rates, with positive primary outcome findings through various sensitivity analyses. These findings were supported by the secondary outcomes of decreased use of potent steroids, decreased SPT, and improved quality of life. However, the sample size was small; thus, some of the uncommon secondary outcomes lacked precision. Furthermore, the SCORAD improvement of 6.9 is below the minimum clinically important difference of 8.5. While omalizumab may serve as an adjunctive therapy in severe refractory atopic dermatitis, the mild improvements reported in this study need to be balanced by the known side effects, cost, and burden of the therapy administration. This was not an industry sponsored study, as it was funded by the NIHR EME Program and Guy’s and St Thomas’ Charity and the NHS Foundation Trust. It should be noted however, that Novartis supplied the omalizumab and placebo used in the study and the senior author also reports getting personal fees from Novartis outside of this study.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health